Method of treatment of androgen-related diseases

Details Method of treatment of androgen-related diseases Method of treatment of androgen-related diseases

1995-06-07

1997-03-11

Jordan, Charles T.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514171, 514172, 514177, A01N 4500

Patent

active

056101503

ABSTRACT:
A method of treatment of androgen-related diseases such as prostate cancer in susceptible male animals, including humans, novel antiandrogens and/or novel sex steroid biosynthesis inhibitors as part of a combination therapy. Sex steroid biosynthesis inhibitors, especially those capable of inhibiting conversion of dehydroepiandrosterone (DHEA) or 4-androstenedione (.DELTA..sup.4 -dione) to natural sex steroida (and testosterone into dihydrotestosterone) in peripheral tissues, are used in combination with antiandrogens usually after blockade of testicular hormonal secretions. Antiestrogens can also be part of the combination therapy. Pharmaceutical compositions and two, three, four and five component kits are useful for such combination treatment.

REFERENCES:
patent: 3995060 (1976-11-01), Neri et al.
patent: 4024248 (1977-05-01), Konig et al.
patent: 4055641 (1977-10-01), Benson et al.
patent: 4087461 (1978-05-01), Robinson
patent: 4100274 (1978-07-01), Dutta et al.
patent: 4118483 (1978-10-01), Konig et al.
patent: 4139638 (1979-02-01), Neri et al.
patent: 4161540 (1979-07-01), Neri et al.
patent: 4191759 (1980-03-01), Johnston et al.
patent: 4235893 (1980-11-01), Brodie
patent: 4329364 (1982-05-01), Neri et al.
patent: 4386080 (1983-05-01), Crossley et al.
patent: 4472382 (1984-09-01), Labrie et al.
patent: 4481190 (1984-11-01), Nestor et al.
patent: 4547493 (1985-10-01), Teutsch et al.
patent: 4634696 (1987-01-01), Teutsch et al.
patent: 4659516 (1987-04-01), Bowler et al.
patent: 4659695 (1987-04-01), Labrie
patent: 4732912 (1988-03-01), Pilgrim et al.
patent: 4751240 (1988-06-01), Bowler et al.
patent: 4760053 (1988-07-01), Labrie
patent: 4760061 (1988-07-01), Edwards et al.
patent: 4775661 (1988-10-01), Labrie
patent: 4822528 (1989-04-01), Columbo et al.
patent: 4895715 (1990-01-01), Neri
patent: 4904661 (1990-02-01), Pilgrim
patent: 5021414 (1991-06-01), Pilgrim et al.
patent: 5023234 (1991-06-01), Labrie
patent: 5053403 (1981-10-01), Orentreich et al.
patent: 5064813 (1991-11-01), Labrie
patent: 5204337 (1993-04-01), Labrie
patent: 5364847 (1994-11-01), Labrie et al.
patent: 5372996 (1994-12-01), Labrie
patent: 5393785 (1995-02-01), Labrie et al.
Auchus Riess, et al., Biochemistry, 1986, 25, 7295-7300.
Beardwell, et al., Cancer Chemo. Pharmacol. (1983) vol. 10, No. 3 pp. 158-160.
Begin, et al., Molecular and Cellular Endocrinology, 58 (1988) 213-219.
Belis, et al., J. Androl., 4, 144-149, 1983.
Bhatnager, et al., Biol. Chem., 253, 811-815, 1978.
Brooks, et al., Proc. Soc. Experimental Biology and Medicine, 169, 67-73 (1982).
Brooks, et al., Steroids 47/1, Jan. 1986 (1-19).
Brooks, et al., The Prostate, vol. 3, No. 1 pp. 35-44 (1982).
Brooks, et al., Endocrinology, vol. 109, No. 3 (1981) pp. 830-836.
Bruchovsky, et al., J. Biol. Chem., vol. 243, No. 8 (1968) pp. 2012-2021.
Bull, et al., Chem. Soc. Chem. Commun., 1986, pp. 451-453.
Chan, et al., Biochem and Biophys Res. Comm., 144, No. 1, 166-171 (1987).
Chang, et al., Biochemistry, 1982, 27, 4102-4109.
Chin, et al., J. Biol. Chem., 250(19), 1975, pp. 7682-7686.
Chin, et al. J. Biol. Chem., 255, 3660-3664, 1980.
Cooke, Jr., Tetrahedron Letters, 22, 1983-1986, 1973.
Corbin, et al., J. Steroid Biochem., 20(6B) 1369, No. A9 (1984).
Coy, et al., Endocrinology, vol. 110 (1982) pp. 1445-1447.
Coy, et al., J. Med. Chem., vol. 19, No. 3 (1976) pp. 423-425.
Debruyne, et al. (1988)Bailli ere's Clin. Oncol. Int'l Pract. and Res., pp. 559-570.
De Klerk, et al., The Prostate, vol. 7 (1985) pp. 1-12.
De Larminat, et al., The Prostate, vol. 5 (1984), pp. 123-140.
Donnelly, "Continuous Subcutaneous Administration of `Zoladex` (ICI 118,630 - An LH-RH Analogue) to Patients with advanced Prostatic Cancer", ICI.
Doorenbos, et al., J. Pharm. Sciences 63(4), 1974, pp. 620-622.
Doorenbos, et al., J. Pharm. Sciences 62(4), 1973, pp. 638-640.
Doorenbos, et al., J. Pharm. Sciences 60(8), 1971, pp. 1234-1235.
Dutta, et al., J. Med. Chem., 21, No. 10, 1018-1024 (1978).
Earnshaw, et al., Clin. Invest., 21, 13-21 (1984).
Erchegyi, et al., Biochem. and Biophys. Research Comm., 100, No. 3, 915-920 (1981).
Farnsworth, Invest. Urology 6(4) 423-427, 1969.
Faure, et al., LHRH and Its Analogs, pp. 337-349 (1984).
Fujimoto, J. Pharm. Soc. Jap, 87:270 (1967).
Furr, et al. J. Endocr., 113, R7-R9, 1987.
Geller, et al., 71st Ann. Meet. Endo. Soc. (1989) No. 1640.
George, et al., "The Effect of A 5-.alpha.-Reductase Inhibitor on Androgen Physiology in the Prepubertal Male Rat", 71st Ann. Endo. Soc. Mtg. No. 1165 (1989).
Gibson, et al., Angew Chem. Int. Ed. 7 (1968) No. 12, pp. 919-930.
Gohring, et al., (1989), World Patent Information, vol. 11, No. 1, pp. 5-10.
Gormley, et al., 71st Ann. Meet. Endo. Soc. (1989) No. 1225.
Green et al., Nature, 320(13) Mar. 1986, pp. 134-139.
Groom, et al., Biochem J., vol. 122 (1971) pp. 125-126.
Grunwell, et al., Steroids, 27(6), 1976, pp. 759-771.
Gyorki, et al., J. Steroidal Biochem. 25(3), 355-358, 1986.
Habenicht, et al., The Prostate II, 313-326, 1987.
Imperato-McGinley, et al., "Comparison of Plasma and Urinary C19 and C21 5.alpha.-Metabolites in Subjects Treated With the 5.alpha.-Reductase Inhibitor MK906 and Male Pseudohermaphrodites with Inherited 5.alpha.-Reductase Deficiency", 71st Ann. Endo. Soc. Mtg., No. 1639 (1989).
Jordan, et al., Endocrinology, 124 (4), 1989, pp. 1717-1726.
Junkmann, (1957) "Long-Acting Steroids In Reproduction", Recent Progr. Horm. Res., 13:1389-1427, Academic Press, New York.
Kadohama, et al., J. Natl. Cancer Inst., 74, No. 2, pp. 475-486 (1985).
Kerle, et al., J. Steroid Biochem. 20 (6B) 1395, No. A61 (1984).
Labrie et al., J. Steroid Biochem. 19(1) 999-1007, 1184.
Labrie, et al. 7th Int. Congress of Endo. 1984, p. 98.
Labrie, et al. Endocrinology 123: 1412-1417, 1988.
Labrie, et al., Important Advances in Oncology, Eds. V. T. De Vita, et al. J. B. Lippincott Company, Philadelphia, pp. 193-217, 1985.
Labrie, The Prostate, 4, 579-594, 1983.
Labrie, et al., Genitourinary Cancer, pp. 157-199 (1987).
Labrie, et al., J. Steroid Biochem., 28, No. 4 (1987) pp. 379-384.
Lambert, et al., Ann. Clin. Biochem. (1986) vol. 23 pp. 225-229.
Lee et al., Steroids 22, 677-685, 1973.
Lee, et al., J. Androl. 2(6) 293-299, 1981.
Lefebrve et al. Prostate 1982, 3661, 569-570 (Chem. Ab., vol. 99, 1983, Abst. 188132r).
Levesque, et al., J. Med. Chem. 1991, 34 1624-1630.
Liang, et al., Endocrinology, vol. 112, No. 4, pp. 1460-1468 (1983).
Liang, et al., The Journal of Biological Chemistry, vol. 259, No. 2, pp. 734-739 (1984).
Lubahn et al. Proc. Natl Acad. Sci. USA 86, 9534-9538, Dec. 1989.
Lubahn et al., Science, 1988 pp. 327-330.
Luthy, et al., J. Steroidal Biochem. 31(5) 845-52, 1988.
Macaulay, et al., J. Steroidal Biochem. 26(5) 535-538, 1987.
McConnell, et al., Journal of Urol., AUA 84th Ann. Meeting, 141, 239A, 280 (1989).
Mobbs, et al., J. Steroidal Biochem., 19(3), 1279-1290, 1983.
Mobbs, 71th An. Meeting of the Endocrine Soc., No. 1410, 1989.
Moore, et al., J. Clin. Invest., vol. 63, pp. 351-357 (1979).
Musto, et al., Endo. Res. Comm. (1977), vol. 4, No. 2, pp. 147-157.
Nayfeh, et al., Steroids 14:3, 1969, pp. 269-283.
Neri et al, J. Steroidal Biochem., 1975(6), pp. 815-819.
Nestor, et al., J. Steroid Biochem., 20 (6B), 1366, No. A3 (1984).
Nestor, et al., Contraceptive and Therapeutic Appl., pp. 3-10, 23-33, 1984.
Neumann, et al., In: Clinics in Oncology, vol. 1, pp. 41-64, 1982.
Petrow, et al., J. Endo., 95, 311-313 (1982).
Plante, et al., J. Steroid Biochem., 31(1), pp. 61-64 (1988).
Potts, et al., Steroids (1978) vol. 32, No. 2, pp. 257-267.
Poyet and Labrie, Mol. Cell. Endocrinol., 42, 283-288, 1985.
Raucher, et al., J. Org. Chem., 1981, 46, 3558-3559.
Redding, Proc. Nat'l Acad. Sci. USA 80 1459-1452, 1984.
Riess, Institut de Chimie, Strasbourg, France (Jul. 31, 1964).
Rivier, et al., J. Steroid Biochem., 20(6B), 1365, No. A1 (1984).
Rivier, et al., Contraceptive and Therapeutic Appl., pp. 11-22 (1984).
Robinson, et al., J. Steroid Biochem. 21, No. 5, 601-605 (1984).
Salman, et al., J. Steroid Biochem, vol. 33, No. 1, pp. 25-31, 1989.
Salman, et al., J. Steroid Biochem., 26, 383-391, 1987.
Santen, LHRH and

Affiliated with

Also associated with

Rating

Method of treatment of androgen-related diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treatment of androgen-related diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of androgen-related diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-443675